Dec. 4 at 4:58 AM
$ADCT Per Chat GPT here is why it was sold off today:
Despite the positive efficacy metrics, the market appears to have focused on some risk factors and uncertainties revealed by the update:
The trial reported two Grade-5 (fatal) adverse events among the patients — that’s ~4.1% of the efficacy-evaluable group; at least one of those was judged treatment-related.
Also, cytokine release syndrome (CRS) — a known and serious safety risk with bispecific therapies — occurred in 36.7% of patients, across dose levels.
For a therapy aimed at salvage / tough lymphoma patients, such safety issues are concerning. They may complicate regulatory approval, adoption by physicians, or limit usage.
The combination therapy remains under early (Phase 1b) investigation and full enrollment is not yet complete — the company expects ~100 total patients at selected dose by 1H
That means long-term safety, durability of responses, and risk/benefit balance remain unclear — high risk even with early efficacy.
